Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betaxolol vs brimonidine to prevent intraocular pressure rise after Nd:YAG posterior capsulotomy
IRCT20200901048577N1Phase 3Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of betaxolol and brimonidine in posterior capsule opacification (PCO) and ocular hypertension (2 arms), sponsored by Semnan University of Medical Sciences. Primary endpoint: Prophylactic effect on post-laser intraocular pressure elevation. Started Aug 2019; status: completed.
02
Drugs
betaxololbrimonidine
03
Conditions
posterior capsule opacification (PCO)ocular hypertension
Beyond the preview
Go deeper on IRCT20200901048577N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200901048577N1.